Novel anti-CD73-IL-2v bispecific fusion protein augments antitumor immunity by alleviating immunosuppressive adenosine pathways in CD8<sup>+</sup> T cells
GI-αCD73/IL-2v bispecific protein is a novel and potent immunocytokine with significant antitumor immunity through cis-binding on CD8<sup>+</sup> T cells.
Authors
- Kook Hwan Kim (ORCID: https://orcid.org/0000-0003-2702-9156)
- Kyungwha Lee
- Haejong Lee
- Junsik Park (ORCID: https://orcid.org/0000-0003-4094-2097)
- Hyuckjun Mok
- Suyoun Park
- Jong‐Il Kim (ORCID: https://orcid.org/0000-0002-7240-3744)
- Sung‐Man Oh
- Young-gyu Cho
- Yaein Amy Shim
- Myoung Ho Jang (ORCID: https://orcid.org/0000-0001-8909-4725)
- Sanghee Lee (ORCID: https://orcid.org/0000-0002-7765-5916)
- Jisoo Kim (ORCID: https://orcid.org/0000-0001-6785-0446)
- Jihyun Kim (ORCID: https://orcid.org/0000-0002-8071-3435)
- Won‐Jae Lee (ORCID: https://orcid.org/0000-0002-1438-8005)
- Eun Jin Lee (ORCID: https://orcid.org/0000-0001-5718-542X)
- Min Park (ORCID: https://orcid.org/0000-0001-5958-7633)
- Seoho Kim
- Yuseong Lee
- Young Min Oh
- Chong Woo Park
- Young Jun Koh
- Kayoung Shin
- Jung-Yun Lee
Institutions
- Yonsei University (KR)
- GI Innovation (South Korea) (KR)
- Osaka International University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1136/jitc-2023-008594
- Citations
- 6
- Primary Topic
- Adenosine and Purinergic Signaling
- Type
- article
- Field-Weighted Citation Impact
- 6.71
Funders
- Korea Drug Development Fund
- Ministry of Science and ICT, South Korea